share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K：外国发行人报告
SEC announcement ·  03/15 20:05
牛牛AI助手已提取核心信息
SciSparc Ltd., a clinical-stage pharmaceutical company, announced the successful dosing of the first patient in its SCI-210 clinical trial for Autism Spectrum Disorder (ASD) on March 14, 2024. The trial is being conducted at the Soroka Medical Center and targets pediatric patients. This marks a significant advancement following the company's recent update on the delivery of its SCI-210 treatment to the clinical site. The treatment comprises a combination of cannabidiol-rich oil and CannAmide, SciSparc's proprietary palmitoylethanolamide-based tablets. The study is designed as a randomized, double-blind, placebo-controlled trial with cross-over, set to last 20 weeks and enroll 60 children. It aims to assess the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. The primary efficacy...Show More
SciSparc Ltd., a clinical-stage pharmaceutical company, announced the successful dosing of the first patient in its SCI-210 clinical trial for Autism Spectrum Disorder (ASD) on March 14, 2024. The trial is being conducted at the Soroka Medical Center and targets pediatric patients. This marks a significant advancement following the company's recent update on the delivery of its SCI-210 treatment to the clinical site. The treatment comprises a combination of cannabidiol-rich oil and CannAmide, SciSparc's proprietary palmitoylethanolamide-based tablets. The study is designed as a randomized, double-blind, placebo-controlled trial with cross-over, set to last 20 weeks and enroll 60 children. It aims to assess the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. The primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc specializes in cannabinoid pharmaceuticals and is also engaged in drug development programs for Tourette Syndrome, Alzheimer’s disease, pain, and status epilepticus. The company cautions that the forward-looking statements in the press release are subject to risks and uncertainties, and actual results may differ materially from those projected.
处于临床阶段的制药公司ScisPARC Ltd. 于2024年3月14日宣布在其针对自闭症谱系障碍（ASD）的 SCI-210 临床试验中成功给第一位患者给药。该试验正在索罗卡医疗中心进行，目标是儿科患者。这标志着继该公司最近向临床场所提供 SCI-210 治疗的最新情况之后取得的重大进展。该疗法包括富含大麻二酚的油和cannaMide（ScisPARC专有的基于棕榈酰乙醇酰胺的片剂）的组合。该研究设计为一项交叉随机、双盲、安慰剂对照试验，将持续20周，招收60名儿童。它旨在评估 SCI-210 与 CBD 单一疗法相比的安全性、耐受性和疗效。主要疗效终点包括异常行为清单社区、临床全球印象改善量表和确定有效治疗剂量。ScisPARC专门研究大麻素药物，还参与图雷特综合症、阿尔茨海默氏病、疼痛和癫痫持续状态的药物开发项目。该公司警告说，新闻稿中的前瞻性陈述受风险和不确定性的影响，实际业绩可能与预期存在重大差异。
处于临床阶段的制药公司ScisPARC Ltd. 于2024年3月14日宣布在其针对自闭症谱系障碍（ASD）的 SCI-210 临床试验中成功给第一位患者给药。该试验正在索罗卡医疗中心进行，目标是儿科患者。这标志着继该公司最近向临床场所提供 SCI-210 治疗的最新情况之后取得的重大进展。该疗法包括富含大麻二酚的油和cannaMide（ScisPARC专有的基于棕榈酰乙醇酰胺的片剂）的组合。该研究设计为一项交叉随机、双盲、安慰剂对照试验，将持续20周，招收60名儿童。它旨在评估 SCI-210 与 CBD 单一疗法相比的安全性、耐受性和疗效。主要疗效终点包括异常行为清单社区、临床全球印象改善量表和确定有效治疗剂量。ScisPARC专门研究大麻素药物，还参与图雷特综合症、阿尔茨海默氏病、疼痛和癫痫持续状态的药物开发项目。该公司警告说，新闻稿中的前瞻性陈述受风险和不确定性的影响，实际业绩可能与预期存在重大差异。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。